ZA200705982B - Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylin-dan-1-yl)-3,3-dimethylpiperazine - Google Patents

Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylin-dan-1-yl)-3,3-dimethylpiperazine

Info

Publication number
ZA200705982B
ZA200705982B ZA200705982A ZA200705982A ZA200705982B ZA 200705982 B ZA200705982 B ZA 200705982B ZA 200705982 A ZA200705982 A ZA 200705982A ZA 200705982 A ZA200705982 A ZA 200705982A ZA 200705982 B ZA200705982 B ZA 200705982B
Authority
ZA
South Africa
Prior art keywords
phenylin
dimethylpiperazine
dan
trans
chloro
Prior art date
Application number
ZA200705982A
Other languages
English (en)
Inventor
Bang-Andersen Benny
Lopez De Diego Heidi
Original Assignee
Lundebeck As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200705982(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundebeck As H filed Critical Lundebeck As H
Publication of ZA200705982B publication Critical patent/ZA200705982B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200705982A 2005-02-16 2006-02-14 Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylin-dan-1-yl)-3,3-dimethylpiperazine ZA200705982B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500239 2005-02-16

Publications (1)

Publication Number Publication Date
ZA200705982B true ZA200705982B (en) 2009-06-24

Family

ID=37908539

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705982A ZA200705982B (en) 2005-02-16 2006-02-14 Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylin-dan-1-yl)-3,3-dimethylpiperazine

Country Status (29)

Country Link
US (2) US7648991B2 (es)
EP (1) EP1853576B1 (es)
JP (1) JP5055135B2 (es)
KR (1) KR101386387B1 (es)
CN (1) CN101119983B (es)
AR (1) AR052909A1 (es)
AT (1) ATE515501T1 (es)
AU (1) AU2006215957B9 (es)
BR (1) BRPI0607436B8 (es)
CA (1) CA2597622C (es)
CY (1) CY1111857T1 (es)
DK (1) DK1853576T3 (es)
EA (1) EA017631B1 (es)
ES (1) ES2368786T3 (es)
HK (1) HK1117525A1 (es)
HR (1) HRP20110645T1 (es)
IL (1) IL184551A (es)
MX (1) MX2007009980A (es)
MY (1) MY148683A (es)
NO (1) NO339863B1 (es)
NZ (1) NZ556397A (es)
PL (1) PL1853576T3 (es)
PT (1) PT1853576E (es)
RS (1) RS51944B (es)
SI (1) SI1853576T1 (es)
TW (1) TWI376373B (es)
UA (1) UA95901C2 (es)
WO (1) WO2006086986A1 (es)
ZA (1) ZA200705982B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004265021B2 (en) 2003-08-18 2010-05-27 H. Lundbeck A/S Succinate and malonate salt of trans-4-(IR,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) * 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
KR20110021754A (ko) * 2008-05-07 2011-03-04 하. 룬드벡 아크티에셀스카브 인지 결함 치료 방법
CA2732613A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
SI2720989T1 (sl) 2011-06-20 2016-11-30 H. Lundbeck A/S Devterirani 1-piperazino-3-fenil indani za zdravljenje shizofrenije
US20210395208A1 (en) 2018-10-29 2021-12-23 H. Lundeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
CN113056457A (zh) 2018-12-03 2021-06-29 H.隆德贝克有限公司 4-((1R,3S)-6-氯-3-苯基-2,3-二氢-1H-茚-1-基)-1,2,2-三甲基哌嗪和4-((1R,3S)-6-氯-3-(苯基-d5)-2,3-二氢-1H-茚-1-基)-2,2-二甲基-1-(甲基-d3)哌嗪的前药

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) * 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
EP0612244B1 (en) 1991-11-05 2001-09-19 Smithkline Beecham Corporation Endothelin receptor antagonists
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
JPH06184132A (ja) 1992-12-22 1994-07-05 Kotobuki Seiyaku Kk ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤
EP0724552B1 (en) 1993-11-30 1997-10-29 Pfizer Inc. Process for preparing a chiral tetralone
CA2132411A1 (en) * 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
WO1999057089A1 (en) * 1998-05-01 1999-11-11 Pfizer Products Inc. Process for the production of enantiomerically pure or optically enriched sertraline-tetralone using continuous chromatography
DE69929689T2 (de) 1998-05-22 2006-11-02 Scios Inc., Fremont Heterocyclische Verbindungen und Verfahren zur Behandlung von Herzversagen und anderer Erkrankungen
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
JP2000351773A (ja) 1999-06-08 2000-12-19 Yamanouchi Pharmaceut Co Ltd フラン誘導体からなる医薬
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
IN187170B (es) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
AU2004265021B2 (en) 2003-08-18 2010-05-27 H. Lundbeck A/S Succinate and malonate salt of trans-4-(IR,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
MX2007009816A (es) 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound

Also Published As

Publication number Publication date
IL184551A (en) 2014-05-28
KR20070103414A (ko) 2007-10-23
ATE515501T1 (de) 2011-07-15
EP1853576A1 (en) 2007-11-14
EA200701740A1 (ru) 2007-12-28
EP1853576B1 (en) 2011-07-06
PL1853576T3 (pl) 2011-12-30
IL184551A0 (en) 2007-10-31
US7648991B2 (en) 2010-01-19
CA2597622A1 (en) 2006-08-24
CA2597622C (en) 2013-11-12
AU2006215957B2 (en) 2011-09-29
AU2006215957B9 (en) 2012-02-16
AR052909A1 (es) 2007-04-11
NO339863B1 (no) 2017-02-13
US8450324B2 (en) 2013-05-28
WO2006086986A1 (en) 2006-08-24
UA95901C2 (en) 2011-09-26
NO20074639L (no) 2007-09-12
KR101386387B1 (ko) 2014-04-25
NZ556397A (en) 2010-06-25
US20080153848A1 (en) 2008-06-26
HRP20110645T1 (hr) 2011-10-31
JP5055135B2 (ja) 2012-10-24
EA017631B1 (ru) 2013-02-28
CN101119983B (zh) 2014-11-12
JP2008530040A (ja) 2008-08-07
TW200640890A (en) 2006-12-01
BRPI0607436B8 (pt) 2021-05-25
MX2007009980A (es) 2007-09-26
HK1117525A1 (en) 2009-01-16
BRPI0607436A2 (pt) 2010-04-06
ES2368786T3 (es) 2011-11-22
TWI376373B (en) 2012-11-11
RS51944B (en) 2012-02-29
CY1111857T1 (el) 2015-11-04
SI1853576T1 (sl) 2011-11-30
BRPI0607436B1 (pt) 2020-10-06
AU2006215957A1 (en) 2006-08-24
DK1853576T3 (da) 2011-09-26
MY148683A (en) 2013-05-31
PT1853576E (pt) 2011-09-28
US20100105699A1 (en) 2010-04-29
CN101119983A (zh) 2008-02-06

Similar Documents

Publication Publication Date Title
HK1123544A1 (en) Process for making trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3- dimethylpiperazine
IL184551A0 (en) Crystalline base of trans -1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
EP1844003A4 (en) NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
IL173589A0 (en) Trans-1 (6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
EP1911743B8 (en) Cyclic amine compound
EP1968608A4 (en) PRACTICAL, COST-EFFECTIVE SYNTHESIS OF UBICHINONES
ZA200801708B (en) Synthesis of 1±-fluoro-25-hydroxy-16-23E-diene-26,27-bishomo-20-EPI-cholecalciferol
IL184531A0 (en) Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
IS8264A (is) Trans-1(6-klór-3-fenýlindan-1-ýl)-3,3-dímetýlpíperasín
AU2004100238A4 (en) Tacomate-taco holder
AU2004907292A0 (en) Support assembly
AU2005904904A0 (en) Snap Cap
AU2005901287A0 (en) New Compound
AU2005901288A0 (en) New Compound
ZAA200500821S (en) Lamp base
AU2004901919A0 (en) New Compound
AU2004906673A0 (en) New Compound
AU2004903491A0 (en) New Compound
AU2004902161A0 (en) New Compound
AU2004900341A0 (en) New Compounds
AU2005906443A0 (en) Support Pole
AU2004900071A0 (en) Pager
AU2004900660A0 (en) Sign holder
AU2005903252A0 (en) Support
AU2005900551A0 (en) Support